These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35082762)

  • 1. Commentary: Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis.
    Zhao LM; Chen XH; Qiu M
    Front Endocrinol (Lausanne); 2021; 12():825100. PubMed ID: 35082762
    [No Abstract]   [Full Text] [Related]  

  • 2. Meta-analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium-glucose co-transporter-2 inhibitors: Implications for the COVID-19 pandemic.
    Patoulias D; Papadopoulos C; Boulmpou A; Doumas M
    Diabetes Obes Metab; 2021 Jul; 23(7):1696-1700. PubMed ID: 33606909
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies.
    Hidayat K; Du X; Shi BM
    Osteoporos Int; 2019 Oct; 30(10):1923-1940. PubMed ID: 31134305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis.
    Cho YK; Kang YM; Lee SE; Lee J; Park JY; Lee WJ; Kim YJ; Jung CH
    Diabetes Metab; 2018 Nov; 44(5):393-401. PubMed ID: 29449146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Narrative review on clinical considerations for patients with diabetes and COVID-19: More questions than answers.
    Katsiki N; Gómez-Huelgas R; Mikhailidis DP; Pérez-Martínez P
    Int J Clin Pract; 2021 Nov; 75(11):e14833. PubMed ID: 34510676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study.
    Pérez-Belmonte LM; Torres-Peña JD; López-Carmona MD; Ayala-Gutiérrez MM; Fuentes-Jiménez F; Jorge Huerta L; Muñoz JA; Rubio-Rivas M; Madrazo M; Garcia MG; Montes BV; Sola JF; Ena J; Ferrer RG; Pérez CM; Ripper CJ; Lecumberri JJN; Acedo IEA; Canteli SP; Cosío SF; Martínez FA; Rodríguez BC; Pérez-Martínez P; Ramos-Rincón JM; Gómez-Huelgas R;
    BMC Med; 2020 Nov; 18(1):359. PubMed ID: 33190637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Not Available].
    Toft E; Rydén M
    Lakartidningen; 2018 Feb; 115():. PubMed ID: 29461566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy of Type 2 Diabetes in Patients with SARS-CoV-2 Infection.
    Bielka W; Przezak A; Pawlik A
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
    Min SH; Yoon JH; Hahn S; Cho YM
    Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights.
    Stoian AP; Papanas N; Prazny M; Rizvi AA; Rizzo M
    J Cardiovasc Pharmacol Ther; 2020 Nov; 25(6):494-496. PubMed ID: 32618198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
    Kramer CK; Ye C; Campbell S; Retnakaran R
    JACC Heart Fail; 2018 Oct; 6(10):823-830. PubMed ID: 30196071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2016; 9(2):229-40. PubMed ID: 26589238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis.
    D'Andrea E; Kesselheim AS; Franklin JM; Jung EH; Hey SP; Patorno E
    Cardiovasc Diabetol; 2020 Sep; 19(1):154. PubMed ID: 32993654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?
    Pitocco D; Tartaglione L; Viti L; Di Leo M; Pontecorvi A; Caputo S
    Diabetes Res Clin Pract; 2020 May; 163():108162. PubMed ID: 32335097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of long-term use of sodium-glucose co-transporter-2 inhibitors on plasma volume status in patients with type 2 diabetes mellitus: Sub-analysis of a prospective, observational study during the COVID-19 pandemic.
    Patoulias D; Papadopoulos C; Zografou I; Katsimardou A; Imprialos K; Stavropoulos K; Tranidou A; Karagiannis A; Doumas M
    Kardiol Pol; 2022; 80(1):80-82. PubMed ID: 34783355
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of a sodium-glucose co-transporter-2 inhibitor versus placebo as an add-on therapy for people with type 2 diabetes inadequately treated with metformin and a dipeptidyl peptidase-4 inhibitor: a systematic review and meta-analysis of randomised controlled trials.
    De Buitléir C; O' Connor E; Satti MM; Shaw J; Liew A
    Diabet Med; 2021 Feb; 38(2):e14409. PubMed ID: 32979231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal outcomes of SGLT2 inhibitors and GLP1 agonists in clinical practice.
    van der Aart-van der Beek AB; Heerspink HJL
    Nat Rev Nephrol; 2020 Aug; 16(8):433-434. PubMed ID: 32541904
    [No Abstract]   [Full Text] [Related]  

  • 19. The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Kawalec P; Mikrut A; Łopuch S
    Diabetes Metab Res Rev; 2014 May; 30(4):269-83. PubMed ID: 24829965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Change in glucose-lowering medication regimens in individuals with type 2 diabetes mellitus during the COVID-19 pandemic in Germany.
    Jacob L; Rickwood S; Rathmann W; Kostev K
    Diabetes Obes Metab; 2021 Apr; 23(4):910-915. PubMed ID: 33319440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.